RE:RE:Next PP forthcoming… @ G1945V: thank you for your feedback.
PMN got my interest in the early months of 2016 (Alzheimer disease). Substantial progresses were made in 2016 and 2017, but since then, management keeps repeating the same old story (with few advances in the other diseases).
While I still believe in PMN, it appears that the next steps (for all diseases) depend on (the (availability of) the Biomarkers, as a preliminary condition to start a clinical study. I will not contest that this conceptual approach might provide major benefits (“rapid and cost effective”) and might become the standard in the years to come.
However, those biomarkers are not yet available (“could generate clinical data in a 2-4 year timeframe”) and it appears to me (but I recognize my entire lack of competence in this regard) that the resulting data (proof of concept, before Phase 1) will confirm or contradict the initial assumptions but not necessarily evidence that PMN has a cure for those diseases…
So, if someone has a better understanding, I will greatly appreciate some valuable inputs.
I concur with your comments about dilution but, except if a partnership deal is arranged (”Near term (3-12 month)”), I’m afraid that, what I call the “stockholder boredom syndrome”, might soon emerge (alternatively will continue).
Having said that, I have been proven wrong so many times....
Good Luck To All!